A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Masuishi, T. [1 ]
Sakai, Y. [1 ]
Matsui, T. [1 ]
Nakamura, R. [1 ]
Anzai, S. [1 ]
Suzuki, Y. [1 ]
Kobori, I. [1 ]
Fukami, Y. [1 ]
Suzuki, K. [1 ]
Tazawa, J. [1 ]
机构：
[1] Tsuchiura Kyodo Gen Hosp, Dept Gastroenterol, Tsuchiura, Ibaraki, Japan
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
10.1093/annonc/mdt459.47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer: CIRIS study
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S557
  • [2] A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis
    Eto, T.
    Masuishi, T.
    Matsui, T.
    Anzai, S.
    Suzuki, Y.
    Fukami, Y.
    Suzuki, K.
    Kusano, F.
    Sakai, Y.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [3] PHASE II STUDY OF IRINOTECAN PLUS CETUXIMAB FOR PRETREATED METASTATIC COLORECTAL CANCER WITH KRAS WILD TYPE
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Utsunomiya, Setsuo
    Muro, Kei
    ANNALS OF ONCOLOGY, 2010, 21 : 13 - 13
  • [4] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [5] A phase II study of bevacizumab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS mutant-type metastatic colorectal cancer.
    Eto, Tetsuya
    Masuishi, Toshiki
    Suzuki, Kohei
    Shibata, Isamu
    Fukami, Yuichi
    Matsui, Toru
    Ichida, Takashi
    Kusano, Fumihiko
    Tazawa, Junichi
    Sakai, Yoshinori
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
    Lang, Istvan
    Koehne, Claus-Henning
    Folprecht, Gunnar
    Rougier, Philippe
    Curran, Desmond
    Hitre, Erika
    Sartorius, Ute
    Griebsch, Ingolf
    Van Cutsem, Eric
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) : 439 - 448
  • [7] Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients
    Terazawa, Tetsuji
    Nishitani, Hitoshi
    Kato, Ken
    Hashimoto, Hironobu
    Akiyoshi, Kohei
    Ito, Yuriko
    Nakamoto, Akihiro
    Iwasa, Satoru
    Nakajima, Takako Eguchi
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E132 - E137
  • [8] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Utsunomiya, Setsuo
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 688 - 693
  • [9] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Tomoya Yokota
    Daisuke Takahari
    Takashi Shibata
    Takashi Ura
    Setsuo Utsunomiya
    Yoshitaka Inaba
    Hidekazu Yamaura
    Yozo Sato
    Mina Najima
    Hiroki Kawai
    Masahiro Tajika
    Akira Sawaki
    Yasushi Yatabe
    Kei Muro
    Investigational New Drugs, 2011, 29 : 688 - 693
  • [10] A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
    Shimoyama, Rai
    Kimura, Tetsuo
    Takaoka, Toshi
    Sakamoto, Kazuki
    Kawamoto, Shunji
    Yoshizaki, Koji
    Negoro, Yuji
    Goda, Fuminori
    Tsuji, Akihito
    Nakayama, Tsuyoshi
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    Niitsu, Yoshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345